mob

Search This Blog

468x60

728

728x90

468,

250

250+300onk

BACKGROUND: Venous thromboembolism (VTE) is a common complication of cancer. This study aimed to evaluate immatur


ABSTRACT


BACKGROUND: Venous thromboembolism (VTE) is a common complication of cancer. This study aimed to evaluate immature platelet fraction (IPF), mean platelet volume (MPV), P-selectin, D-dimer, and thrombin generation (TG) as predictive biomarkers for VTE and further the improvement of existing risk assessment models (RAMs).


METHODS: A prospective, observational, exploratory study was conducted on ambulatory cancer patients with indication for systemic chemotherapy. Baseline RAMs included the Khorana-, Vienna Cancer, Thrombosis-, Protecht-, ONKOTEV-, and Catscore. IPF, MPV, P-selectin, D-dimer, and TG were analysed at baseline and 3-month follow-up.


RESULTS: We enrolled 100 patients, of whom 89 completed the follow-up. Frequent tumour types were breast (30%), gastric (14%), gynaecological (14%), and colorectal (14%) cancer. Ten of the 89 patients (11.2%) developed VTE. The highest VTE rate was observed in patients with cholangiocarcinoma (3/5; 60%). Baseline D-dimer levels but not IPF, MPV, or P-selectin were associated with the risk of developing VTE (HR 6.9; p = 0.021). None of the RAMs showed statistical significance in predicting VTE. Peak thrombin and endogenous thrombin potential were lower in patients who developed VTE. Biomarker changes between baseline and follow-up were not associated with VTE risk.


CONCLUSIONS: VTE risk was well predicted by baseline D-dimer levels. Adding D-dimer could improve existing RAMs to better identify patients who may benefit from primary VTE prophylaxis. The VTE risk among patients with cholangiocarcinoma should be further evaluated.


PMID:32580190 | DOI:10.1159/000508271

05:35

Cardiotoxicity News

PubMed articles on: Cardio-Oncology

Cardiovascular disease and asymptomatic childhood cancer survivors: Current clinical practice


Bottinor WJ, et al. Cancer Med 2020.

 

No comments:

Post a Comment

اكتب تعليق حول الموضوع

ACERUMEN، زجاجة جرعة واحدة

  جديد   عرض تقديمي 10 زجاجات الموزع أو الشركة المصنعة زينيث فارما تعبير عوامل التوتر السطحي الخفيفة (أسيل ساركوزينات الصوديوم وإستر السكروز...

Search This Blog